PATENT CLAIM ANALYSIS

Application Number: 16035833
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2018-11
Patent Classification: ["514", "479000"]

Abstract:
Described herein is a method for treating a central nervous system disorder, said method comprising steps of first transnasally administering to or immediately adjacent the sphenopalatine ganglion a first pharmaceutical agent that effectively enhances permeability of the blood-brain barrier; and thereafter administering a second pharmaceutical agent with known efficacious value for action upon central nervous system tissue. The central nervous system disorder may be related directly to the brain or to other central nervous system tissues and cells.

Claim (Index 5):
The method of  claim 1 , wherein, the transnasal administration step include targeted spraying from within a posterior portion of the nasal cavity directed laterally and superiorly toward the sphenopalatine ganglion such that a volume of the first pharmaceutical agent is delivered onto nasal mucosa immediately overlying the sphenopalatine ganglion.

Metadata:
- Claim Count in Document: 50.0
- Percentile: 95.0
- Lexical Diversity: 1.49091
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15296069', '14845012', '14522136', '12414300', '12946576']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7540630133280991
- 35 USC 102 Novelty (BERT): 0.6589091589958302
- Combined Prediction Score: 0.7445476278948723
- Mean Citation Score: 375.03298800000016
- Max Citation Score: 729.9094
- Similarity Product: 573.6731232331276

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test